Taysha Gene Therapies (TSHA) Debt to Equity (2022 - 2025)
Historic Debt to Equity for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $0.23.
- Taysha Gene Therapies' Debt to Equity fell 5201.47% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.23, marking a year-over-year decrease of 5201.47%. This contributed to the annual value of $0.61 for FY2024, which is 1365.21% up from last year.
- Per Taysha Gene Therapies' latest filing, its Debt to Equity stood at $0.23 for Q3 2025, which was down 5201.47% from $0.17 recorded in Q2 2025.
- Taysha Gene Therapies' Debt to Equity's 5-year high stood at $40.01 during Q4 2022, with a 5-year trough of -$3.65 in Q3 2023.
- For the 4-year period, Taysha Gene Therapies' Debt to Equity averaged around $2.81, with its median value being $0.54 (2023).
- Per our database at Business Quant, Taysha Gene Therapies' Debt to Equity plummeted by 44648.68% in 2023 and then soared by 13362.95% in 2024.
- Over the past 4 years, Taysha Gene Therapies' Debt to Equity (Quarter) stood at $40.01 in 2022, then tumbled by 98.65% to $0.54 in 2023, then rose by 13.65% to $0.61 in 2024, then plummeted by 62.2% to $0.23 in 2025.
- Its Debt to Equity stands at $0.23 for Q3 2025, versus $0.17 for Q2 2025 and $0.77 for Q1 2025.